Mindray Overview
- Year Founded
-
1991

- Status
-
Public
- Employees
-
18,044

- Stock Symbol
-
300760

- Investments
-
14
- Share Price
-
$34.60
- (As of Friday Closing)
Mindray General Information
Description
Shenzhen Mindray Bio-Medical Electronics Co Ltd is a developer, manufacturer, and supplier of medical devices. The company is focused on the medical industry in the fields of Patient Monitoring & Life Support, InVitro Diagnostics, and Medical Imaging.
Contact Information
Website
www.mindray.comCorporate Office
- Mindray Building, Keji 12th Road South
- Hi-tech Industrial Park, Nanshan
- Shenzhen, Guangdong 518057
- China
Corporate Office
- Mindray Building, Keji 12th Road South
- Hi-tech Industrial Park, Nanshan
- Shenzhen, Guangdong 518057
- China
Mindray Stock Performance
As of 14-Mar-2025, Mindray’s stock price is $34.60. Its current market cap is $41.9B with 1.21B shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$34.60 | $33.78 | $31.36 - $50.08 | $41.9B | 1.21B | 5.21M | $1.42 |
Mindray Financials Summary
As of 30-Sep-2024, Mindray has a trailing 12-month revenue of $5.17B.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 48,502,386 | 46,902,115 | 52,872,782 | 70,678,131 |
Revenue | 5,170,304 | 4,937,455 | 4,508,941 | 3,913,469 |
EBITDA | 1,832,043 | 1,865,681 | 1,706,336 | 1,443,191 |
Net Income | 1,725,389 | 1,637,092 | 1,426,552 | 1,239,191 |
Total Assets | 8,214,350 | 6,762,972 | 6,775,359 | 5,977,789 |
Total Debt | 42,901 | 41,606 | 34,282 | 37,219 |
Mindray Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Mindray Comparisons
Industry
Financing
Details
Mindray Competitors (29)
One of Mindray’s 29 competitors is Vyaire Medical, a Private Equity-Backed company based in Mettawa, IL.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Vyaire Medical | Private Equity-Backed | Mettawa, IL | ||||
Philips | Corporation | Amsterdam, Netherlands | ||||
Fukuda Denshi | Corporation | Tokyo, Japan | ||||
Drägerwerk | Corporation | Lubeck, Germany | ||||
Hill-Rom | Corporation | Essen, Germany |
Mindray Patents
Mindray Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20250044432-A1 | Ultrasonic elasticity imaging method and ultrasonic imaging apparatus | Pending | 01-Aug-2023 | ||
EP-4497756-A2 | Antibody, kit, detection method and sample analyzer for detecting thyroid stimulating hormone | Pending | 25-Jul-2023 | ||
US-20250044304-A1 | Antibody, kit, detection method and sample analyzer for detecting thyroid stimulating hormone | Pending | 25-Jul-2023 | ||
US-20250034236-A1 | Anti-thyroglobulin antibody, kit and use thereof | Pending | 25-Jul-2023 | ||
EP-4509526-A2 | Anti-thyroglobulin antibody, kit and use thereof | Pending | 25-Jul-2023 | C07K16/18 |
Mindray Signals
Mindray Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Mindray Investments & Acquisitions (14)
Mindray’s most recent deal was a PIPE with APT Medical for . The deal was made on 15-Apr-2024.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
APT Medical | 15-Apr-2024 | PIPE | Therapeutic Devices | ||
APT Medical | 29-Jan-2024 | PIPE | Therapeutic Devices | ||
DiaSys Diagnostic Systems | 29-Nov-2023 | Merger/Acquisition | Diagnostic Equipment | ||
Adicon Clinical Laboratory | 19-Jun-2023 | IPO | Laboratory Services (Healthcare) | ||
DINGS' Intelligent Control Technology | 13-Apr-2023 | IPO | Industrial Supplies and Parts |
Mindray ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
22.34 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile

Healthcare
Industry
of 581
Rank
Percentile

Medical Devices
Subindustry
of 196
Rank
Percentile

Mindray Affiliates
Subsidiaries (3)
Name | Industry | Location | Year Founded |
---|---|---|---|
HyTest | Turku, Finland | 1994 | |
DiaSys Diagnostic Systems | Holzheim, Germany | 1991 | |
Shanghai Long Island Biotechnology Company | Fengxian, China |
Mindray FAQs
-
When was Mindray founded?
Mindray was founded in 1991.
-
Where is Mindray headquartered?
Mindray is headquartered in Shenzhen, China.
-
What is the size of Mindray?
Mindray has 18,044 total employees.
-
What industry is Mindray in?
Mindray’s primary industry is Medical Supplies.
-
Is Mindray a private or public company?
Mindray is a Public company.
-
What is Mindray’s stock symbol?
The ticker symbol for Mindray is 300760.
-
What is the current stock price of Mindray?
As of 14-Mar-2025 the stock price of Mindray is $34.60.
-
What is the current market cap of Mindray?
The current market capitalization of Mindray is $41.9B.
-
What is Mindray’s current revenue?
The trailing twelve month revenue for Mindray is $5.17B.
-
Who are Mindray’s competitors?
Vyaire Medical, Philips, Fukuda Denshi, Drägerwerk, and Hill-Rom are some of the 29 competitors of Mindray.
-
What is Mindray’s annual earnings per share (EPS)?
Mindray’s EPS for 12 months was $1.42.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »